Sutro Biopharma stock hits 52-week low at $2.45
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sutro Biopharma (STRO)Sutro Biopharma stock price live, this page displays NASDAQ STRO stock exchange data. View the STRO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sutro Biopharma real time stock price chart below.
What Is the Sutro Biopharma Stock Price Today?
The Sutro Biopharma stock price today is 2.200.
What Is the Stock Symbol for Sutro Biopharma?
The stock ticker symbol for Sutro Biopharma is STRO.
Is STRO the Same as $STRO?
$STRO is a common way to refer to the Sutro Biopharma ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the NASDAQ stock exchange.
Is Sutro Biopharma a Good Stock to Buy?
Determining whether Sutro Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Sutro Biopharma share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STRO quote. (ISIN: US8693671021)
What Is the Sutro Biopharma Stock Price Today?
The Sutro Biopharma stock price today is 2.200.
What Is the Stock Symbol for Sutro Biopharma?
The stock ticker symbol for Sutro Biopharma is STRO.
Is STRO the Same as $STRO?
$STRO is a common way to refer to the Sutro Biopharma ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the NASDAQ stock exchange.
Is Sutro Biopharma a Good Stock to Buy?
Determining whether Sutro Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Sutro Biopharma share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STRO quote. (ISIN: US8693671021)
2.200
-0.250(-10.20%)
Closed
Pre Market
2.260+0.060(+2.73%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.190
2.480
52 wk Range
2.190
6.130
STRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1902.480
52 wk Range
2.1906.130
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
STRO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
11.500
Upside
+422.727%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Sutro Biopharma Company Profile
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company’s pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma SWOT Analysis
Analyst Outlook | Gain insights from analyst perspectives, with price targets ranging up to $17, reflecting confidence in Sutro's clinical progress and financial stability |
Market Opportunities | Delve into Sutro's potential to capture significant market share in oncology, leveraging its proprietary technologies and expanding into new indications |
Financial Strength | Discover how Sutro's robust $388.3M cash position and strategic partnerships provide a solid foundation for long-term growth and clinical development |
Pipeline Progress | Explore Sutro's advancing clinical trials, including Luvelta for ovarian and lung cancers, showcasing potential for market expansion and therapeutic breakthroughs |
Compare STRO to Peers and Sector
Metrics to compare | STRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTROPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −2.6x | −0.6x | |
PEG Ratio | −0.04 | −0.03 | 0.00 | |
Price / Book | 1.6x | 2.8x | 2.6x | |
Price / LTM Sales | 1.1x | 24.6x | 3.2x | |
Upside (Analyst Target) | 328.6% | 354.6% | 45.4% | |
Fair Value Upside | Unlock | 14.5% | 7.7% | Unlock |
Analysts' Recommendations
10 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.500
(+422.73% Upside)
People Also Watch
FAQ
What Is the Sutro Biopharma (STRO) Stock Price Today?
The Sutro Biopharma stock price today is 2.20
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Sutro Biopharma?
The stock symbol for Sutro Biopharma is "STRO."
What Is the Sutro Biopharma Market Cap?
As of today, Sutro Biopharma market cap is 181.41M.
What is Sutro Biopharma Earnings Per Share?
The Sutro Biopharma EPS is -1.73.
What Is the Next Sutro Biopharma Earnings Date?
Sutro Biopharma will release its next earnings report on Mar 26, 2025.
From a Technical Analysis Perspective, Is STRO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.